A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

被引：1
|
作者：
Kotb, Rami [1 ]
Gul, Engin [2 ]
Reece, Donna E. [3 ,4 ]
机构：
[1] Canc Care Manitoba, Winnipeg, MB, Canada
[2] Canadian Myeloma Res Grp, Toronto, ON, Canada
[3] Canadian Myeloma Res Grp Formerly MCRN, Toronto, ON, Canada
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-15363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4767
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
    Goldschmidt, Hartmut
    Mai, Elias K.
    Bertsch, Uta
    Fenk, Roland
    Nievergall, Eva
    Tichy, Diana
    Besemer, Britta
    Durig, Jan
    Schroers, Roland
    von Metzler, Ivana
    Haenel, Mathias
    Mann, Christoph
    Asemissen, Anne M.
    Heilmeier, Bernhard
    Weinhold, Niels
    Huhn, Stefanie
    Kriegsmann, Katharina
    Luntz, Steffen P.
    Holderried, Tobias A. W.
    Trautmann-Grill, Karolin
    Gezer, Deniz
    Klaiber-Hakimi, Maika
    Mueller, Martin
    Khandanpour, Cyrus
    Knauf, Wolfgang
    Scheid, Christof
    Munder, Markus
    Geer, Thomas
    Riesenberg, Hendrik
    Thomalla, Jorg
    Hoffmann, Martin
    Raab, Marc S.
    Salwender, Hans J.
    Weisel, Katja C.
    LANCET HAEMATOLOGY, 2022, 9 (11): : E810 - E821
  • [32] Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
    Perrot, Aurore
    Roussel, Murielle
    Lauwers-Cances, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    Touzeau, Cyrille
    Facon, Thierry
    Mariette, Clara
    Schiano, Jean-Marc
    Gay, Julie
    Montes, Lydia
    Ranta, Dana
    Huguet, Amandine
    Wuilleme, Soraya
    Dejoie, Thomas
    Devlamynck, Laure
    Corre, Jill
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [33] Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study
    Luttwak, Efrat
    Gatt, Moshe
    Lavi, Noa
    Tadmor, Tamar
    Kreiniz, Natalia
    Benyamini, Noam
    Horowitz, Netanel
    Suriu, Celia
    Avivi, Irit
    Trestman, Svetlana
    Mittelman, Moshe
    Ram, Ron
    Rouvio, Ory
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E296 - E296
  • [34] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Derman, Ben A.
    Major, Ajay
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Alcantar, Luis
    Libao, Bernadette M.
    McIver, Amanda
    Andreatos, Evangelia
    Major, Sarah
    Wolfe, Brittany
    Gorski, Martha
    Karrison, Theodore G.
    Stefka, Andrew
    Jakubowiak, Andrzej
    BLOOD, 2021, 138
  • [35] A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Parmar, Harsh
    Phull, Pooja
    Doucette, Kimberly
    Feinman, Rena
    Zenreich, Joshua
    Anand, Palka
    Ivanovski, Kristin
    Pace, Monique
    Biamonte, Lisa
    Campanaro, Martha
    McClendon, Trina
    Limbad, Chandani
    BaboolallAracena, Samanta
    Aleman, Adolfo
    Unawane, Rashmi
    Pendergrass, Elizabeth
    Layton, Marie
    Breeze, Genevieve
    Chappell, Aimee
    Della Pia, Alexandra
    Kumka, Susan
    Siegel, David S.
    BLOOD, 2023, 142
  • [36] A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study
    O'Gorman, Peter
    O'Dwyer, Michael E.
    Gilligan, Oonagh
    Quinn, John
    Coyne, Mark
    Krawczyk, Janusz
    Murphy, Philip T.
    McAlester, Lourdes del Rosario
    Harraghy, Orna
    Cormican, Orlaith
    Lenihan, Elizabeth
    Egan, Keith
    Perera, Meegahage Ratnakanthi
    Crotty, Gerard
    Hayden, Patrick J.
    Hennessy, Brian
    O'Leary, Hilary M.
    Scott, Kathleen
    Parker, Imelda
    Cunnane, Michele
    Marron, Jacinta
    Connell, Aoife
    Coghlan, Elizabeth
    Laubach, Jacob P.
    Richardson, Paul G.
    BLOOD, 2016, 128 (22)
  • [37] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Lavoie-Gagnon, Claudie
    St-Gelais, Jonathan
    Adam, Jean-Philippe
    Viens, Daniel
    Gagne, Felixe
    Decarie, Yann
    Lemieux-Blanchard, Emilie
    BLOOD, 2017, 130
  • [38] Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial
    Goldschmidt, Hartmut
    Mai, Elias K.
    Durig, Jan
    Scheid, Christof
    Weisel, Katja C.
    Kunz, Christina
    Bertsch, Uta
    Hielscher, Thomas
    Munder, Markus
    Lindemann, Hans-Walter
    Huegle-Doerr, Barbara
    Hose, Dirk
    Seckinger, Anja
    Huhn, Stefanie
    Jauch, Anna
    Rabold, Bernhard
    Elmaagacli, Ahmet
    Gerecke, Christian
    Brossart, Peter
    Goerner, Martin
    Bernhard, Helga
    Hoffmann, Martin
    Hillengass, Jens
    Raab, Marc-Steffen S.
    Blau, Igor Wolfgang
    Hanel, Mathias
    Salwender, Hans Jurgen
    BLOOD, 2017, 130
  • [39] MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma
    Kortuem, M.
    Manteca, Mateos M. V.
    Grosicki, S.
    Kim, K.
    Negre, E.
    Vandendries, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 182 - 182
  • [40] Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
    Takezako, Naoki
    Ohta, Kensuke
    Handa, Hiroshi
    Hori, Mitsuo
    Kinoshita, Gen
    Shelat, Suresh
    Miyoshi, Masafumi
    Kubo, Kohmei
    BLOOD, 2017, 130
12345